Comparative Pharmacology
Head-to-head clinical analysis: CLAFORAN versus CLAFORAN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLAFORAN versus CLAFORAN IN DEXTROSE 5 IN PLASTIC CONTAINER.
CLAFORAN vs CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a bactericidal cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation, and activating autolytic enzymes.
1-2 g IV/IM every 8 hours. Maximum dose: 12 g/day in divided doses.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
0.8-1.4 hours in normal renal function (prolonged to 11-30 hours in severe renal impairment, CrCl <10 mL/min). No clinically relevant accumulation with standard dosing in renal impairment with dose adjustment.
Terminal elimination half-life is approximately 0.6-1.2 hours in adults with normal renal function. In neonates, it is prolonged (2-6 hours). In renal impairment, half-life extends significantly (up to 15-30 hours in anuria), requiring dose adjustment.
Primarily renal (80-90% unchanged in urine via glomerular filtration and tubular secretion); biliary/fecal <10%.
Primarily renal: approximately 60-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Small amounts are eliminated in bile (<10%) and feces (<1%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic